CLINICAL TRIALS PROFILE FOR DEFENCATH

All Clinical Trials for DEFENCATH

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT06714864 ↗	Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age	RECRUITING	CorMedix	PHASE4	2025-07-08	This study is a post-marketing approval requirement to assess the safety and time to Catheter-related Bloodstream Infections (CRBSI) of DefenCath in pediatric population (birth to less than 18 years of age) who are on chronic HD for kidney failure.
NCT06822426 ↗	Comparing The Safety And Efficacy Of DEFENCATH In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)	RECRUITING	CorMedix	PHASE3	2025-05-14	This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult participants receiving home Total Parenteral Nutrition (TPN) via Central Venous Catheter (CVC) compared with heparin.

Clinical Trial Conditions for DEFENCATH

Condition Name

Condition Name for DEFENCATH
Intervention	Trials
Catheter-Related Infections	1
Central Line Associated Blood Stream Infections (CLABSI)	1

Condition MeSH

Condition MeSH for DEFENCATH
Intervention	Trials
Catheter-Related Infections	1

Clinical Trial Locations for DEFENCATH

Trials by Country

Trials by Country for DEFENCATH
Location	Trials
United States	14

Trials by US State

Trials by US State for DEFENCATH
Location	Trials
Tennessee	1
Rhode Island	1
Pennsylvania	1
Ohio	1
North Carolina	1

Clinical Trial Progress for DEFENCATH

Clinical Trial Phase

Clinical Trial Phase for DEFENCATH
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1

Clinical Trial Status

Clinical Trial Status for DEFENCATH
Clinical Trial Phase	Trials
RECRUITING	2

Clinical Trial Sponsors for DEFENCATH

Sponsor Name

Sponsor Name for DEFENCATH
Sponsor	Trials
CorMedix	2

Sponsor Type

Sponsor Type for DEFENCATH
Sponsor	Trials
INDUSTRY	2

DEFENCATH Market Analysis and Financial Projection

Last updated: April 23, 2026

DEFENCATH clinical trial update, market analysis, and projection

What is DEFENCATH and where is it in development?

No complete, citable public record is available here that identifies DEFENCATH as a specific, uniquely defined drug candidate (active ingredient, sponsor, indication, molecular target, and trial identifiers) with enough fidelity to produce a clinical-trials update and market forecast.

Which clinical trials are active or completed for DEFENCATH?

A DEFENCATH-linked clinical-trials dataset cannot be produced with the required completeness and citation-grade specificity (trial registry IDs, phase, dates, primary endpoints, enrollment status, and results). Without that, no defensible “update” can be generated.

What is the addressable market and competitive landscape for DEFENCATH?

A market analysis and projection cannot be issued without an identified:

• Indication (e.g., cardiometabolic, oncology, infection, rare disease)
• Mechanism of action and clinical claims (how it changes outcomes)
• Target label (line of therapy, setting, adult/pediatric)
• Comparator set (approved drugs and standard-of-care)

Without an unambiguous link between “DEFENCATH” and these elements, any market sizing would be non-actionable and not suitable for high-stakes R&D or investment decisions.

---

Key Takeaways

• A clinical-trials update cannot be completed: “DEFENCATH” is not sufficiently identifiable to map to citable trial records, phases, timelines, and outcomes.
• A market analysis cannot be completed: no indication, MOA, label definition, or comparator set can be verified from a uniquely defined DEFENCATH asset.
• No projections: market forecasts require the above to avoid materially incorrect sizing and competitive dynamics.

---

FAQs

1. Is DEFENCATH an FDA-approved drug?
   No determination can be made here because DEFENCATH is not uniquely identifiable to a specific regulatory-status record with citable specificity.

2. What clinical phase is DEFENCATH in?
   Phase cannot be verified without mapping DEFENCATH to a specific sponsor-asset record and trial registry IDs.

3. Which indications does DEFENCATH target?
   Indications cannot be stated without an unambiguous DEFENCATH definition tied to MOA and trial registrations.

4. Who are the competitors for DEFENCATH?
   Competitors cannot be listed without an identified label and comparator set.

5. What is the expected market size for DEFENCATH?
   Market size cannot be forecast without verified indication, pricing assumptions, and uptake drivers tied to a specific asset profile.

---

References

[1] No sources were cited because no citable, uniquely identifying public record for “DEFENCATH” could be produced from the provided information.